<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7A548FB1-2906-495F-9C5E-59F0EE55EF4A"><gtr:id>7A548FB1-2906-495F-9C5E-59F0EE55EF4A</gtr:id><gtr:name>Mathematical, Physical &amp; Life Sciences Division</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EC7A6DA2-C477-4998-A849-39BDA4A62A76"><gtr:id>EC7A6DA2-C477-4998-A849-39BDA4A62A76</gtr:id><gtr:name>Harvard University</gtr:name><gtr:address><gtr:line1>12 Oxford Street</gtr:line1><gtr:postCode>02138</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9DF2B135-0959-424C-A504-9681702AF06B"><gtr:id>9DF2B135-0959-424C-A504-9681702AF06B</gtr:id><gtr:name>Center for Cooperative Research in Biosciences (CIC bioGUNE)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7A548FB1-2906-495F-9C5E-59F0EE55EF4A"><gtr:id>7A548FB1-2906-495F-9C5E-59F0EE55EF4A</gtr:id><gtr:name>Mathematical, Physical &amp; Life Sciences Division</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC7A6DA2-C477-4998-A849-39BDA4A62A76"><gtr:id>EC7A6DA2-C477-4998-A849-39BDA4A62A76</gtr:id><gtr:name>Harvard University</gtr:name><gtr:address><gtr:line1>12 Oxford Street</gtr:line1><gtr:postCode>02138</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9DF2B135-0959-424C-A504-9681702AF06B"><gtr:id>9DF2B135-0959-424C-A504-9681702AF06B</gtr:id><gtr:name>Center for Cooperative Research in Biosciences (CIC bioGUNE)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B6F90BFD-2660-441C-A2C4-51EC8ECB6A4C"><gtr:id>B6F90BFD-2660-441C-A2C4-51EC8ECB6A4C</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>fersht</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MC_EX_G0901534"><gtr:id>6065BF8F-E4A2-43AD-A908-5C3229F296DC</gtr:id><gtr:title>Structural biology of the tumour suppressor p53 and its complexes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_EX_G0901534</gtr:grantReference><gtr:abstractText>The body has defence mechanisms against cancer that involve a protein called p53. This protein also has important roles in many other biological processes, ranging from fertility to ageing. When p53 receives signals that a cell is becoming cancerous, the protein sets into action a train of events that eventually lead to the cancer cell being destroyed. For cancer cells to survive, the activities of p53 have to be eliminated. About half of human cancers have their p53 being disabled by a mutation, most likely caused by environmental damage or radiation. In many cancers, there are raised levels of proteins that inactivate or destroy p53. Our studies examine the shapes of p53 and the other proteins and how they all fit together. These studies will provide fundamental information for designing new anti-cancer drugs that will protect p53.</gtr:abstractText><gtr:technicalSummary>Intrinsically disordered domains are now known to be crucial, functional components of many proteins, especially those involved in cell signalling and regulation of the cell cycle. The presence of disordered regions prevents those proteins being crystallised for structural studies, and so solution of their structures is a major challenge, requiring techniques other than x-ray crystallography. The tumour suppressor p53 is an archetypical example of such a protein, as are its negative regulators MDM2 and MDMX. p53 is inactivated directly by mutation in ~50% of human cancers and its apoptopic pathways impaired in the remainder, often by raised levels of MDM2 and MDMX. We have recently solved the structure of p53 in solution using a combination of state-of-the-art NMR spectroscopy, small-angle-x-ray scattering, other biophysical and structural methods, protein engineering and computation. We now wish to do the same for MDMX and MDM2, and their complexes with p53. We wish to reconstruct the structure of p53 and its complexes in solution in order to understand the relationship between p53s structure and activity and how it is regulated by post-translational modification and interaction with other partner proteins. These studies will provide fundamental information on the control of the cell cycle and aid in the development of novel anti-cancer drugs. We have the necessary preliminary data to ensure that these studies should be successful.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-05-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Center for Cooperative Research in Biosciences (CIC bioGUNE)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Electron Microscopy</gtr:description><gtr:id>1DDD37B0-C919-4441-BC76-F45F29F07163</gtr:id><gtr:impact>17620598, 21178074</gtr:impact><gtr:partnerContribution>They performed electron microscopy experiments and analysed data.</gtr:partnerContribution><gtr:piContribution>We prepared proteins and designed experiments.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard Medical School</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Biological Chemistry &amp; Molecular Pharmacology (BCMP)</gtr:department><gtr:description>Single molecule studies</gtr:description><gtr:id>5E85A888-AA22-43DE-A5F8-85FBB45F19ED</gtr:id><gtr:impact>18424488, 21178072</gtr:impact><gtr:partnerContribution>They performed experiments and analysed data.</gtr:partnerContribution><gtr:piContribution>We provided samples, did experiments and analysed data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mathematical, Physical &amp; Life Sciences Division</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Mass Spectrometry</gtr:description><gtr:id>1EA261E6-4A07-44FB-BD1B-624D1459305B</gtr:id><gtr:impact>19667193, 19815500, 21457718, 21525412</gtr:impact><gtr:partnerContribution>Provided mass spectrometry facilities and intellectual input</gtr:partnerContribution><gtr:piContribution>We did the experiments and analysis, with technical assistance from collaborators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Plenary Lecture at IUBMB, Taiwan</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2C86A5C6-4536-47AB-A99D-8E945AE76ABD</gtr:id><gtr:impact>Discussions

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gave Cornforth lecture at Sussex University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>84184327-C404-42CC-B05F-CB05ADCE2F1A</gtr:id><gtr:impact>Talk sparked questions and discussion

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gave a seminar at Parnas Meeting in Jerusalem</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E48FC6B7-8E11-4B25-A0F3-5E213D7FE716</gtr:id><gtr:impact>Discussions

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Special Lecture at Trinity College Dublin</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>511493F3-AEB2-4B71-9C0D-26EECBE2006F</gtr:id><gtr:impact>Sparked discussions and questions

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at Sperling Memorial Meeting, Rehovoth</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A8EB490E-5DCE-40CA-B866-7F02A3C25CE5</gtr:id><gtr:impact>Discussion/Questions

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at Protein Evolution Meeting in Stockholm</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8E9222AB-A0E2-46EA-BAB7-CEEC890F023F</gtr:id><gtr:impact>Discussions

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spoke at Spetses Summer School</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AFCEBBBB-65DA-4575-A29B-15A7998AD146</gtr:id><gtr:impact>Discussions

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Lecture at Protein Aggregation Meeting in Umea</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>402DEC9C-0ECA-4F64-85A4-415492EB589F</gtr:id><gtr:impact>Questions and discussions

N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1459538</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Support for frontier research (ERC) Advanced Grant</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>GA 268506</gtr:fundingRef><gtr:id>B50A77F3-0B9E-449F-8BA7-15370B0540A3</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS. Basis for novel anti-cancer drugs.</gtr:description><gtr:id>A81207E3-1E79-4BB6-AA73-2B0E34AFAF87</gtr:id><gtr:impact>Scientific breakthrough in stabilizing p53 mutants.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2009136175</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Drug leads</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91DEAFF8-28A8-4EA1-A428-4D8E9DF33C2C"><gtr:id>91DEAFF8-28A8-4EA1-A428-4D8E9DF33C2C</gtr:id><gtr:title>The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.</gtr:title><gtr:parentPublicationTitle>Annual review of biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4154</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/75695187-DC61-417C-AA55-56AC7018B2A8"><gtr:id>75695187-DC61-417C-AA55-56AC7018B2A8</gtr:id><gtr:title>Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/30b8c9248043a823a38c7d999a910671"><gtr:id>30b8c9248043a823a38c7d999a910671</gtr:id><gtr:otherNames>Vogel SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F2032AE3-5FEE-4160-88E9-164AA32416ED"><gtr:id>F2032AE3-5FEE-4160-88E9-164AA32416ED</gtr:id><gtr:title>Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/975956da1f2786b34701712920bae0e0"><gtr:id>975956da1f2786b34701712920bae0e0</gtr:id><gtr:otherNames>Wilcken R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A7DE1B1A-2FA0-408E-A637-10A37CC8D0FE"><gtr:id>A7DE1B1A-2FA0-408E-A637-10A37CC8D0FE</gtr:id><gtr:title>Don't waste good methods on bad buffers and ambiguous data.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1fb7adef0ce22657c6ddda02c27fcffb"><gtr:id>1fb7adef0ce22657c6ddda02c27fcffb</gtr:id><gtr:otherNames>Huang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B1A4D8F-35DB-4C87-B54C-56A056AA9599"><gtr:id>0B1A4D8F-35DB-4C87-B54C-56A056AA9599</gtr:id><gtr:title>Profile of Martin Karplus, Michael Levitt, and Arieh Warshel, 2013 nobel laureates in chemistry.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71aa684c0844cc59acddac5e6ffc8e1e"><gtr:id>71aa684c0844cc59acddac5e6ffc8e1e</gtr:id><gtr:otherNames>Fersht AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1ED8BF12-D592-473C-89C8-A42ABE5806A7"><gtr:id>1ED8BF12-D592-473C-89C8-A42ABE5806A7</gtr:id><gtr:title>MDMX contains an autoinhibitory sequence element.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29cb0932b02405bd4d180264cf9205cb"><gtr:id>29cb0932b02405bd4d180264cf9205cb</gtr:id><gtr:otherNames>Bista M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7AF1D158-F2F6-4E0F-AA52-2C9486969F52"><gtr:id>7AF1D158-F2F6-4E0F-AA52-2C9486969F52</gtr:id><gtr:title>Electrocatalytic monitoring of metal binding and mutation-induced conformational changes in p53 at picomole level.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af8194678a2d4f846e829c5114cdbdc3"><gtr:id>af8194678a2d4f846e829c5114cdbdc3</gtr:id><gtr:otherNames>Palecek E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6985E20-13AE-41E2-A918-0CB86205CD0D"><gtr:id>C6985E20-13AE-41E2-A918-0CB86205CD0D</gtr:id><gtr:title>Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/975956da1f2786b34701712920bae0e0"><gtr:id>975956da1f2786b34701712920bae0e0</gtr:id><gtr:otherNames>Wilcken R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8F75C7A-42CA-4314-9146-0864126FD624"><gtr:id>D8F75C7A-42CA-4314-9146-0864126FD624</gtr:id><gtr:title>Intrinsically disordered p53 and its complexes populate compact conformations in the gas phase.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a28f2ad89feef82a76a258eb44756964"><gtr:id>a28f2ad89feef82a76a258eb44756964</gtr:id><gtr:otherNames>Pagel K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9614134C-A5C8-4676-8826-904339FECA64"><gtr:id>9614134C-A5C8-4676-8826-904339FECA64</gtr:id><gtr:title>Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7f7847864fcf397b5215878a560bd6d"><gtr:id>d7f7847864fcf397b5215878a560bd6d</gtr:id><gtr:otherNames>Melero R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/47B34421-912F-4C89-911F-D2DB7110EAA7"><gtr:id>47B34421-912F-4C89-911F-D2DB7110EAA7</gtr:id><gtr:title>A single-molecule characterization of p53 search on DNA.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d5ffde5f2bc841e507b67923452aae4"><gtr:id>4d5ffde5f2bc841e507b67923452aae4</gtr:id><gtr:otherNames>Tafvizi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C96DCB4-42FE-4C30-862C-87DC9B097B39"><gtr:id>2C96DCB4-42FE-4C30-862C-87DC9B097B39</gtr:id><gtr:title>Small molecule induced reactivation of mutant p53 in cancer cells.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42f7c7c6107a6cd7198876022cb295cf"><gtr:id>42f7c7c6107a6cd7198876022cb295cf</gtr:id><gtr:otherNames>Liu X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E38401C-B561-43B0-8F89-90BBA774E302"><gtr:id>1E38401C-B561-43B0-8F89-90BBA774E302</gtr:id><gtr:title>Design of a molecular support for cryo-EM structure determination.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/662f0dd817d537bfc0b8c1af9ed657ef"><gtr:id>662f0dd817d537bfc0b8c1af9ed657ef</gtr:id><gtr:otherNames>Martin TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF49DB0C-82A2-4756-B290-5BD6DB8F1586"><gtr:id>BF49DB0C-82A2-4756-B290-5BD6DB8F1586</gtr:id><gtr:title>Structure and kinetic stability of the p63 tetramerization domain.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2cb10fc9c59c4712409caddcf226407a"><gtr:id>2cb10fc9c59c4712409caddcf226407a</gtr:id><gtr:otherNames>Natan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41C72554-DF34-433E-B610-9D01854F1A74"><gtr:id>41C72554-DF34-433E-B610-9D01854F1A74</gtr:id><gtr:title>First-order rate-determining aggregation mechanism of p53 and its implications.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3da4986ddd49ef7b9f44694642ebbed8"><gtr:id>3da4986ddd49ef7b9f44694642ebbed8</gtr:id><gtr:otherNames>Wang G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8AF6D523-2BDD-417B-8C78-AA0BD450483C"><gtr:id>8AF6D523-2BDD-417B-8C78-AA0BD450483C</gtr:id><gtr:title>Tracing the evolution of the p53 tetramerization domain.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A98788A5-5C11-4743-AAF7-297D8BD0075E"><gtr:id>A98788A5-5C11-4743-AAF7-297D8BD0075E</gtr:id><gtr:title>Long-range modulation of chain motions within the intrinsically disordered transactivation domain of tumor suppressor p53.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ed440822dd541c7efa8706b5cd232af"><gtr:id>8ed440822dd541c7efa8706b5cd232af</gtr:id><gtr:otherNames>Lum JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/157DDDB3-DE3A-4755-A2BB-6BA7BC3C988B"><gtr:id>157DDDB3-DE3A-4755-A2BB-6BA7BC3C988B</gtr:id><gtr:title>Evaluating Drosophila p53 as a model system for studying cancer mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f119326379946603af68904f5b68bdab"><gtr:id>f119326379946603af68904f5b68bdab</gtr:id><gtr:otherNames>Herzog G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/21326800-2FFB-47C1-8CE1-FFCEB1471B4F"><gtr:id>21326800-2FFB-47C1-8CE1-FFCEB1471B4F</gtr:id><gtr:title>Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/975956da1f2786b34701712920bae0e0"><gtr:id>975956da1f2786b34701712920bae0e0</gtr:id><gtr:otherNames>Wilcken R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A5D99EA-A5B0-47AF-A9F9-0879B07159C2"><gtr:id>5A5D99EA-A5B0-47AF-A9F9-0879B07159C2</gtr:id><gtr:title>Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A424355F-2CCA-45A8-A471-A6D9240E4530"><gtr:id>A424355F-2CCA-45A8-A471-A6D9240E4530</gtr:id><gtr:title>Domain-domain interactions in full-length p53 and a specific DNA complex probed by methyl NMR spectroscopy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29cb0932b02405bd4d180264cf9205cb"><gtr:id>29cb0932b02405bd4d180264cf9205cb</gtr:id><gtr:otherNames>Bista M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/185096A1-9677-4C0D-8D05-B475CF0877CD"><gtr:id>185096A1-9677-4C0D-8D05-B475CF0877CD</gtr:id><gtr:title>2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a62dcf05c10c862cb00ccbd30aa8408"><gtr:id>2a62dcf05c10c862cb00ccbd30aa8408</gtr:id><gtr:otherNames>Bauer MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F3F8415D-8F71-4475-B669-255EE12D263F"><gtr:id>F3F8415D-8F71-4475-B669-255EE12D263F</gtr:id><gtr:title>Sequence-dependent sliding kinetics of p53.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/69a91e85746457becfcc6291be176c04"><gtr:id>69a91e85746457becfcc6291be176c04</gtr:id><gtr:otherNames>Leith JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F4518185-9C27-4537-9786-9433B000BBF2"><gtr:id>F4518185-9C27-4537-9786-9433B000BBF2</gtr:id><gtr:title>Stability of p53 homologs.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/365e8411668a1c816fb8dc4f1175c17d"><gtr:id>365e8411668a1c816fb8dc4f1175c17d</gtr:id><gtr:otherNames>Brandt T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4662F54-CE03-4851-A7F0-C21104327A6C"><gtr:id>A4662F54-CE03-4851-A7F0-C21104327A6C</gtr:id><gtr:title>Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2cb10fc9c59c4712409caddcf226407a"><gtr:id>2cb10fc9c59c4712409caddcf226407a</gtr:id><gtr:otherNames>Natan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0947E348-7481-4246-AE3C-975C7C88500C"><gtr:id>0947E348-7481-4246-AE3C-975C7C88500C</gtr:id><gtr:title>Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b1a132d87b18ba5ebb04320694837d1"><gtr:id>7b1a132d87b18ba5ebb04320694837d1</gtr:id><gtr:otherNames>Arbely E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3FAC51D-5147-4040-8D7B-33AF32720057"><gtr:id>C3FAC51D-5147-4040-8D7B-33AF32720057</gtr:id><gtr:title>Reply to Campos and Mu&amp;ntilde;oz: Why phosphate is a bad buffer for guanidinium chloride titrations.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71aa684c0844cc59acddac5e6ffc8e1e"><gtr:id>71aa684c0844cc59acddac5e6ffc8e1e</gtr:id><gtr:otherNames>Fersht AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_EX_G0901534</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>